Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 28Rectal Neoplasms 6Colonic Neoplasms 6Stomach Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasm Metastasis 3Neutropenia 2Neoplasms 2Colorectal Cancer Metastatic 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Advanced Solid Tumors 2mCRC 1Spinocerebellar Degenerations 1Solid Tumor Cancer 1Sarcoma, Ewing 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Microsatellite-stable Colorectal Cancer 1Metastatic Gastric Adenocarcinoma 1Lung Neoplasms 1High-grade Extra Pulmonary Neuroendocrine Cancer 1HER2 IHC3+ Advanced Colorectal Cancer 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1

Interventions

Cisplatin 26Paclitaxel 21pembrolizumab 15Radiotherapy 13Carboplatin 13tislelizumab 12Fluorouracil 12Drug Therapy 11Irinotecan 9toripalimab 8Esophagectomy 8Oxaliplatin 6Nivolumab 6Capecitabine 6Neoadjuvant Therapy 5Leucovorin 5Docetaxel 5lenvatinib 4camrelizumab 4Taxes 4Radiation 4Levoleucovorin 4Immune Checkpoint Inhibitors 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4spartalizumab 3sintilimab 3apatinib 3Itraconazole 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × trifluridine tipiracil drug combination × 1 year × Clear all
NCT07142421 2025-08-26

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

First Affiliated Hospital of Zhejiang University

Phase 2 Active not recruiting
35 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡